ResearcherFirst Hospital of China Medical UniversityNo recent work listed
Xingda Wu
Matched on OpenAlex author ID A5045443838. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2016: 4 papers · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper
Papers 8
- Liver metastasis of pancreatic cancer: the new choice at the crossroads. Last author DOI 10.21037/hbsn-22-489↗
- Inactivation of ATF-2 enhances epithelial-mesenchymal transition and gemcitabine sensitivity in human pancreatic cancer cells. Co-author DOI 10.1002/jcb.27734↗
- Silencing of ATF2 inhibits growth of pancreatic cancer cells and enhances sensitivity to chemotherapy. First author DOI 10.1002/cbin.10760↗
- HIF1/2α mediates hypoxia-induced LDHA expression in human pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.15266↗
- siRNA-Mediated SBF2 Silencing May Inhibit Pancreatic Cancer Cells via Attenuation of the TGF-β Signaling Pathway. Co-author DOI 10.1177/1533034615580724↗
- Screening for genes and subnetworks associated with pancreatic cancer based on the gene expression profile. Co-author DOI 10.3892/mmr.2016.5007↗
- Gene expression profile analysis of pancreatic cancer based on microarray data. Co-author DOI 10.3892/mmr.2016.5021↗
- Identification of disease-associated pathways in pancreatic cancer by integrating genome-wide association study and gene expression data. Co-author DOI 10.3892/ol.2016.4637↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zhe Liu · 4 shared papers, 2016–2023 · strength 0.58
- Paper Liver metastasis of pancreatic cancer: the new choice at the crossroads. DOI 10.21037/hbsn-22-489↗
- Paper Inactivation of ATF-2 enhances epithelial-mesenchymal transition and gemcitabine sensitivity in human pancreatic cancer… DOI 10.1002/jcb.27734↗
- Paper Screening for genes and subnetworks associated with pancreatic cancer based on the gene expression profile. DOI 10.3892/mmr.2016.5007↗
- Jin Long · 4 shared papers, 2016 · strength 0.30
- Paper siRNA-Mediated SBF2 Silencing May Inhibit Pancreatic Cancer Cells via Attenuation of the TGF-β Signaling Pathway. DOI 10.1177/1533034615580724↗
- Paper Screening for genes and subnetworks associated with pancreatic cancer based on the gene expression profile. DOI 10.3892/mmr.2016.5007↗
- Paper Gene expression profile analysis of pancreatic cancer based on microarray data. DOI 10.3892/mmr.2016.5021↗
- Yuanhong Xu · 4 shared papers, 2016 · strength 0.30
- Paper siRNA-Mediated SBF2 Silencing May Inhibit Pancreatic Cancer Cells via Attenuation of the TGF-β Signaling Pathway. DOI 10.1177/1533034615580724↗
- Paper Screening for genes and subnetworks associated with pancreatic cancer based on the gene expression profile. DOI 10.3892/mmr.2016.5007↗
- Paper Gene expression profile analysis of pancreatic cancer based on microarray data. DOI 10.3892/mmr.2016.5021↗
- Chunlin Ge · 3 shared papers, 2016 · strength 0.23
- Paper siRNA-Mediated SBF2 Silencing May Inhibit Pancreatic Cancer Cells via Attenuation of the TGF-β Signaling Pathway. DOI 10.1177/1533034615580724↗
- Paper Screening for genes and subnetworks associated with pancreatic cancer based on the gene expression profile. DOI 10.3892/mmr.2016.5007↗
- Paper Identification of disease-associated pathways in pancreatic cancer by integrating genome-wide association study and gen… DOI 10.3892/ol.2016.4637↗
- Shaowei Song · 2 shared papers, 2017–2019 · strength 0.21
- Gang Ma · 1 shared paper, 2019 · strength 0.12
- Fanbin Meng · 1 shared paper, 2017 · strength 0.08
- Mu Li · 1 shared paper, 2017 · strength 0.08
- Zhe Liu · 1 shared paper, 2016 · strength 0.08
- Zhe Liu · 1 shared paper, 2016 · strength 0.08
- Chunlin Ge · 1 shared paper, 2016 · strength 0.08
- Bo Li · 1 shared paper, 2017 · strength 0.06
- Xingang Cui · 1 shared paper, 2017 · strength 0.06
- Chenghao Shao · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.